St. Jude Plans Trial To Study Renal Denervation Outcomes
This article was originally published in The Gray Sheet
Landmark trial will evaluate if reductions in blood pressure caused by renal denervation translate to clinical improvements in patients with hard-to-treat hypertension.
You may also be interested in...
St. Jude Halts U.S. Renal Denervation Trial, Citing Slow Patient Enrollment
Patient-recruitment challenges have led St. Jude to halt a U.S. clinical trial of its EnligHTN renal denervation system. The company says it is working with FDA to design a new trial.
Research In Brief
St. Jude launches first U.S. trial of its renal denervation system. Universal decolonization reduces ICU infections better than screening-based approaches. More research news.
EuroPCR in Brief
New clinical data from St. Jude Medical’s and Boston Scientific’s trials of renal denervation devices to treat hypertension show progress in the development of these novel blood pressure therapies, but both companies remain behind Medtronic. More news from EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions.